>>Focal therapy and CyberKnife for localised PCa (UroSource, Netherland)
Friday, 27 March 2009- At the recent 24th Annual EAU Congress held in Stockholm, Dr. Giuseppe Morgia (Messina, Italy) lectured for a European School of Urology (ESU) course regarding emerging treatment procedures for localised prostate cancer such as the Cyberknife, a technique which he said offers several distinct advantages but with a high price tag that hampers the wider use of this new technology.
In his concluding remarks, Morgia summarised the benefits and drawbacks of the Cyberknife system. Benefits include: short treatment course; potent radiation dose within the prostate; less invasive than HDR barchytherapy, and the sharp treatment margin reduces radiation exposure to surrounding tissues.
Amongst the drawbacks are the minimal publications on treatment outcomes; long-term effectiveness has not been confirmed; sharp margin could miss cancer cells if they spread outside the prostate; complications and QoL are not standardised, the high cost of the equipment and the existence of few active centres.